Defining a dose-response relationship for prostate external beam radiotherapy

Journal of Medical Imaging and Radiation Oncology

Volumn 57, Issue 2, 2013, Pages 237-246

  Trada, Yuvnik ^a   Plank, Ash ^b   Martin, Jarad ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Toowoomba Specialist Centre   (Australia)

^c CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

Author keywords

biochemical failure; dose response relationship; prostatic neoplasm; radiation; radiotherapy; systemic review

Indexed keywords

ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER CONTROL; CANCER RISK; CORRELATION ANALYSIS; DOSE RESPONSE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HORMONAL THERAPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE TUMOR; RADIATION DOSE; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ALGORITHMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84875832367     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12008     Document Type: Article

References (43)

1. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-1105.
2. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A,. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007; 68: 682-689.
3. Diez P, Vogelius IS, Bentzen SM,. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1066-1071.
4. van Tol-Geerdink JJ, Stalmeier PF, Pasker-de Jong PC, et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 2006; 64: 534-543.
5. Viani GA, Stefano EJ, Afonso SL,. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-1418.
6. King CR, Kapp DS,. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 2008; 71: 346-350.
7. Cheung R, Tucker SL, Lee AK, et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 993-1002.
8. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH,. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2011; 82: e17-34.
9. Schulz RJ, Kagan AR,. Dose escalation in the radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1289-1291.
10. Roach M 3rd, Hanks G, Thames H Jr., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-974.
11. Ahmad S, Vogds BJ, McKenna F, Vlachaki MT,. Tumor control probability (TCP) in prostate cancer: role of radiobiological parameters and radiation dose escalation. J Xray Sci Technol 2009; 17: 347-354.
12. O'Rourke SF, McAneney H, Hillen T,. Linear quadratic and tumour control probability modelling in external beam radiotherapy. J Math Biol 2009; 58: 799-817.
13. Team RDC,. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, 2011.
14. Di Staso M, Bonfili P, Gravina GL, et al. Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer. BJU Int 2010; 106: 1458-1462.
15. Krauss D, Kestin L, Ye H, et al. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1064-1071.
16. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011; 79: 1310-1317.
17. Martin JM, Bayley A, Bristow R, et al. Image guided dose escalated prostate radiotherapy: still room to improve. Radiat Oncol 2009; 4: 50.
18. Liauw SL, Weichselbaum RR, Rash C, et al. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat 2009; 8: 201-206.
19. Crook J, Ludgate C, Malone S, et al. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 327-333.
20. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-487.
21. Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011; 80: 1056-1063.
22. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010; 28: 1106-1111.
23. Al-Mamgani A, Heemsbergen WD, Levendag PC, Lebesque JV,. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiother Oncol 2010; 96: 13-18.
24. Okunieff P, Morgan D, Niemierko A, Suit HD,. Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys 1995; 32: 1227-1237.
25. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166: 876-881.
26. Pollack A, Smith LG, von Eschenbach AC,. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000; 48: 507-512.
27. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA,. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 2000; 55: 85-90.
28. Crook J, Borg J, Evans A, et al. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1100 patients. Int J Radiat Oncol Biol Phys 2011; 80: 1323-1329.
29. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 330-337.
30. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H,. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006; 176 (4 Pt 1): 1415-1419.
31. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-118.
32. Martinez A,. RTOG 0815 Protocol Information. 2010. 12/10/2010 [Cited 21 May 2012.] Available from URL: http://www.rtog.org/ClinicalTrials/ProtocolTable/ StudyDetails.aspx?study=0815
33. Hayden AJ, Martin JM, Kneebone AB, et al. Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma. J Med Imaging Radiat Oncol 2010; 54: 513-525.
34. O'Daniel JC, Dong L, Zhang L, et al. Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 883-891.
35. Langen KM, Jones DT,. Organ motion and its management. Int J Radiat Oncol Biol Phys 2001; 50: 265-278.
36. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-1253.
37. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 1084-1089.
38. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A,. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys 2007; 68: 1424-1430.
39. Yeoh EE, Botten RJ, Butters J, Matteo ACD, Holloway RH, Fowler J,. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011; 81: 1271-1278.
40. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78: 11-18.
41. Zelefsky MJ, Yamada Y, Pei X, et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011; 77: 986-990.
42. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 (Suppl 1): 22-29.
43. Martin JM, Supiot S, Berthold DR,. Pharmacotherapeutic management of locally advanced prostate cancer: current status. Drugs 2011; 71: 1019-1041.